

# Sara Alonso-Alvarez

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7449263/sara-alonso-alvarez-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34 papers	311 citations	10 h-index	17 g-index
41 ext. papers	417 ext. citations	3.6 avg, IF	2.46 L-index

#	Paper	IF	Citations
34	Development of an algorithm for the identification of leukemic hematolymphoid neoplasms in Primary Care patients. <i>Diagnosis</i> , <b>2021</b> , 8, 239-247	4.2	
33	Genetic complexity impacts the clinical outcome of follicular lymphoma patients. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 11	7	0
32	Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. <i>European Journal of Cancer</i> , <b>2021</b> , 157, 132-139	7.5	1
31	Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-Cell Lymphoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
30	Reply to Brown et al: Correct application of variant classification guidelines in germline mutated disorders to assist clinical diagnosis <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 248-249	1.9	
29	Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 2780-2792	7.5	6
28	Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited mutations without a pre-existing platelet disorder. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 181-184	1.9	3
27	Expression of CD47 antigen in Reed-Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 782-785	3.6	4
26	Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 52	7	4
25	Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 480-491	4.5	14
24	Altered Immunophenotypes on Leukemic and/or Monocytic Cells from Acute Myeloid Leukemia Highly Predict for Nucleophosmin Gene Mutation. <i>Blood</i> , <b>2019</b> , 134, 2687-2687	2.2	
23	Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma. <i>Hematological Oncology</i> , <b>2019</b> , 37, 215-218	1.3	1
22	Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 4145-4145	2.2	
21	Chronic Lymphocytic Leukemia Patients with IGH Rearrangements Are Characterized By a Distinct Genetic Landscape with Prognostic Implications. <i>Blood</i> , <b>2018</b> , 132, 3129-3129	2.2	
20	Prognostic Value of Minimal Residual Disease before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. <i>Blood</i> , <b>2018</b> , 132, 5733-5733	2.2	
19	Is there a role for the international prognostic index in follicular lymphoma?. <i>Annals of Hematology</i> , <b>2018</b> , 97, 713-715	3	2
18	Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. <i>Lancet Haematology</i> , <b>2018</b> , 5, e359-e367	14.6	47

17	Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of $\beta_2$ -microglobulin yields a more accurate GELTAMO-IPI. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 918-928	4.5	50
16	Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome. <i>Hematological Oncology</i> , <b>2017</b> , 35, 520-527	1.3	15
15	Plitidepsin: design, development, and potential place in therapy. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 253-264	4.4	46
14	From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. <i>Blood Cancer Journal</i> , <b>2017</b> , 7, e591	7	14
13	Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 699-708	4.5	42
12	The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment. <i>Annals of Hematology</i> , <b>2017</b> , 96, 1833-1840	3	9
11	The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1144-1152	1.9	16
10	Lymphoma Heterogeneity: Three Different Histological Pictures and One Unique Clone. <i>Case Reports in Hematology</i> , <b>2016</b> , 2016, 3947510	0.7	3
9	Protocolo de práctica asistencial de las linfocitosis crónicas. <i>Medicine</i> , <b>2016</b> , 12, 1245-1248	0.1	
8	Adenopatías generalizadas, exantema cutáneo y fiebre en mujer con antecedente de síndrome de fatiga crónica y fibromialgia. <i>Medicine</i> , <b>2016</b> , 12, 1253.e1-1253.e3	0.1	
7	Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. <i>Haematologica</i> , <b>2015</b> , 100, e289-91	6.6	10
6	Acute graft-versus-host disease and bronchiolitis obliterans after autologous stem cell transplantation in a patient with multiple myeloma. <i>Clinical Case Reports (discontinued)</i> , <b>2015</b> , 3, 370-5	0.7	3
5	Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group. <i>Blood</i> , <b>2015</b> , 126, 3944-3944	2.2	2
4	Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). <i>Blood</i> , <b>2015</b> , 126, 582-582	2.2	13
3	Prognostic Impact, Phenotypic and Molecular Characterization of Concordant and Discordant Bone Marrow Involvement in Patients with Diffuse Large b-Cell Lymphoma. <i>Blood</i> , <b>2015</b> , 126, 3871-3871	2.2	
2	PD-1 and PD-L1 Are Overexpressed in the "Intermediate CD14+CD16+" and "Non Classical CD14lowCD16+" but Not in the "Classical CD14+CD16-" Monocytes in the Peripheral Blood of Chronic Myelomonocytic Leukemia. <i>Blood</i> , <b>2015</b> , 126, 1694-1694	2.2	
1	Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project. <i>Blood</i> , <b>2015</b> , 126, 3955-3955	2.2	